Expedition Therapeutics Secures $165 Million Series A and Executes License Agreement With Fosun Pharma
Singapore – October 11, 2025 – Cooley advised Expedition Therapeutics, a biotechnology company developing therapies for novel inflammatory and respiratory diseases, on its oversubscribed and upsized $165 million Series A financing and its license agreement with Fosun Pharma Industrial.
Proceeds from the Series A financing will advance Expedition’s lead candidate, EXPD-101, through a global Phase 2 study in chronic obstructive pulmonary disease. Sofinnova Investments and Novo Holdings co-led the round, with additional participation from Forbion, Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, and existing investors BVF Partners and Venrock Healthcare Capital Partners.
In August 2025, Expedition acquired exclusive worldwide rights – excluding mainland China, Hong Kong and Macau – from Fosun Pharma to develop and commercialize EXPD-101 in all indications. EXPD-101 is currently advancing in a Phase 2 bronchiectasis study led by Fosun Pharma within China.
Lawyers Patrick Loofbourrow, Lila Hope, Allison Pang, Zack Gong and Michael Shen led the Cooley team advising Expedition Therapeutics.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.